2025

Mayne, Kaitlin J., Walker, Heather, Elyan, Benjamin M.P. ORCID: https://orcid.org/0000-0001-8848-1395, Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123, Welsh, Paul ORCID: https://orcid.org/0000-0002-7970-3643, Lang, Ninian L. ORCID: https://orcid.org/0000-0001-8441-6887, Sattar, Naveed A. ORCID: https://orcid.org/0000-0002-1604-2593, Pell, Jill P. ORCID: https://orcid.org/0000-0002-8898-7035, Ho, Frederick K. ORCID: https://orcid.org/0000-0001-7190-9025 and Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 (2025) Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study. European Journal of Preventive Cardiology, (doi: 10.1093/eurjpc/zwaf514) (In Press)

Judge, P. K. et al. (2025) The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrology Dialysis Transplantation, 40(6), pp. 1175-1186. (doi: 10.1093/ndt/gfae263) (PMID:39533115) (PMCID:PMC12209857)

Mayne, K. J. et al. (2025) Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 40(4), pp. 720-730. (doi: 10.1093/ndt/gfae203) (PMID:39277784) (PMCID:PMC7616479)

The EMPA-KIDNEY Collaborative Group and (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 392(8), pp. 777-787. (doi: 10.1056/NEJMoa2409183) (PMID:39453837) (PMCID:PMC7616743)

2024

Mayne, Kaitlin J., Hanlon, Peter ORCID: https://orcid.org/0000-0002-5828-3934 and Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 (2024) Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes, Obesity and Metabolism, 26(S6), pp. 43-54. (doi: 10.1111/dom.15625) (PMID:38699995)

Pinter, Jule, Canaud, Bernard, Mayne, Kaitlin J., Stuard, Stefano, Moissl, Ulrich, Kooman, Jeroen, Jager, Kitty J., Chesnaye, Nicholas C., Smyth, Brendan and Genser, Bernd (2024) Associations of abnormal fluid status, plasma sodium disorders, and low dialysate sodium with mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology, 19(11), pp. 1444-1452. (doi: 10.2215/cjn.0000000000000552) (PMID:39292852)

Fletcher, R. A. et al. (2024) Effects of Sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD: a meta-analysis of CKD progression trials. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1180-1182. (doi: 10.2215/CJN.0000000000000470) (PMID:38622766)

Mayne, K. J. et al. (2024) Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1119-1129. (doi: 10.2215/cjn.0000000000000498) (PMID:38949880)

Nangaku, M. et al. (2024) Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology, 28(6), pp. 588-595. (doi: 10.1007/s10157-024-02489-4) (PMID:38643286) (PMCID:PMC11116192)

Mayne, K. J. et al. (2024) Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease. Journal of the American Society of Nephrology, 35(2), pp. 202-215. (doi: 10.1681/ASN.0000000000000271) (PMID:38082486) (PMCID:PMC7615589)

Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)

EMPA-KIDNEY Collaborative Group and (2024) Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes and Endocrinology, 12(1), pp. 39-50. (doi: 10.1016/S2213-8587(23)00321-2) (PMID:38061371) (PMCID:PMC7615591)

Judge, P. et al. (2024) Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes and Endocrinology, 12(1), pp. 51-60. (doi: 10.1016/S2213-8587(23)00322-4) (PMID:38061372)

2023

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Mayne, Kaitlin J., Sullivan, Michael K. ORCID: https://orcid.org/0000-0002-3800-2330 and Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 (2023) Sex and gender differences in the management of chronic kidney disease and hypertension. Journal of Human Hypertension, (doi: 10.1038/s41371-023-00843-9) (Early Online Publication)

Mayne, Kaitlin J., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 and Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 (2023) Cardiovascular complications of chronic kidney disease. Medicine, 51(3), pp. 190-195. (doi: 10.1016/j.mpmed.2022.12.008)

Mayne, Kaitlin J., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178, Rutherford, Elaine, Thomson, Peter C., Traynor, Jamie P., Dey, Vishal ORCID: https://orcid.org/0000-0002-5108-4158, Lang, Ninian N. ORCID: https://orcid.org/0000-0001-8441-6887 and Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 (2023) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, 16(3), pp. 512-520. (doi: 10.1093/ckj/sfac248) (PMID:36865003) (PMCID:PMC9972818)

Mayne, Kaitlin J., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 and Herrington, William G. (2023) Bioimpedance in CKD: an untapped resource? Nephrology Dialysis Transplantation, 38(3), pp. 583-585. (doi: 10.1093/ndt/gfac275) (PMID:36260361) (PMCID:PMC9976732)

The EMPA-KIDNEY Collaborative Group and (2023) Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), pp. 117-127. (doi: 10.1056/nejmoa2204233) (PMID:36331190) (PMCID:PMC7614055)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

2022

Baigent, C. et al. (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, 400(10365), pp. 1788-1801. (doi: 10.1016/S0140-6736(22)02074-8) (PMID:36351458) (PMCID:PMC7613836)

Mayne, Kaitlin J., Shemilt, Richard, Keane, David F., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178, Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 and Herrington, William G. (2022) Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review. Journal of Cardiac Failure, 28(11), pp. 1628-1641. (doi: 10.1016/j.cardfail.2022.08.005) (PMID:36038013)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Rankin, Alastair J. ORCID: https://orcid.org/0000-0001-9031-481X, Mayne, Kaitlin, Allwood-Spiers, Sarah, Hall Barrientos, Pauline, Roditi, Giles, Gillis, Keith A. ORCID: https://orcid.org/0000-0003-0003-4000 and Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 (2022) Will advances in functional renal magnetic resonance imaging translate to the nephrology clinic? Nephrology, 27(3), pp. 223-230. (doi: 10.1111/nep.13985) (PMID:34724286)

2021

Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)

Articles

Mayne, Kaitlin J., Walker, Heather, Elyan, Benjamin M.P. ORCID: https://orcid.org/0000-0001-8848-1395, Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123, Welsh, Paul ORCID: https://orcid.org/0000-0002-7970-3643, Lang, Ninian L. ORCID: https://orcid.org/0000-0001-8441-6887, Sattar, Naveed A. ORCID: https://orcid.org/0000-0002-1604-2593, Pell, Jill P. ORCID: https://orcid.org/0000-0002-8898-7035, Ho, Frederick K. ORCID: https://orcid.org/0000-0001-7190-9025 and Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 (2025) Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study. European Journal of Preventive Cardiology, (doi: 10.1093/eurjpc/zwaf514) (In Press)

Judge, P. K. et al. (2025) The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrology Dialysis Transplantation, 40(6), pp. 1175-1186. (doi: 10.1093/ndt/gfae263) (PMID:39533115) (PMCID:PMC12209857)

Mayne, K. J. et al. (2025) Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation, 40(4), pp. 720-730. (doi: 10.1093/ndt/gfae203) (PMID:39277784) (PMCID:PMC7616479)

The EMPA-KIDNEY Collaborative Group and (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 392(8), pp. 777-787. (doi: 10.1056/NEJMoa2409183) (PMID:39453837) (PMCID:PMC7616743)

Mayne, Kaitlin J., Hanlon, Peter ORCID: https://orcid.org/0000-0002-5828-3934 and Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 (2024) Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes, Obesity and Metabolism, 26(S6), pp. 43-54. (doi: 10.1111/dom.15625) (PMID:38699995)

Pinter, Jule, Canaud, Bernard, Mayne, Kaitlin J., Stuard, Stefano, Moissl, Ulrich, Kooman, Jeroen, Jager, Kitty J., Chesnaye, Nicholas C., Smyth, Brendan and Genser, Bernd (2024) Associations of abnormal fluid status, plasma sodium disorders, and low dialysate sodium with mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology, 19(11), pp. 1444-1452. (doi: 10.2215/cjn.0000000000000552) (PMID:39292852)

Fletcher, R. A. et al. (2024) Effects of Sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD: a meta-analysis of CKD progression trials. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1180-1182. (doi: 10.2215/CJN.0000000000000470) (PMID:38622766)

Mayne, K. J. et al. (2024) Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clinical Journal of the American Society of Nephrology, 19(9), pp. 1119-1129. (doi: 10.2215/cjn.0000000000000498) (PMID:38949880)

Nangaku, M. et al. (2024) Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology, 28(6), pp. 588-595. (doi: 10.1007/s10157-024-02489-4) (PMID:38643286) (PMCID:PMC11116192)

Mayne, K. J. et al. (2024) Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease. Journal of the American Society of Nephrology, 35(2), pp. 202-215. (doi: 10.1681/ASN.0000000000000271) (PMID:38082486) (PMCID:PMC7615589)

Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)

EMPA-KIDNEY Collaborative Group and (2024) Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes and Endocrinology, 12(1), pp. 39-50. (doi: 10.1016/S2213-8587(23)00321-2) (PMID:38061371) (PMCID:PMC7615591)

Judge, P. et al. (2024) Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes and Endocrinology, 12(1), pp. 51-60. (doi: 10.1016/S2213-8587(23)00322-4) (PMID:38061372)

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Mayne, Kaitlin J., Sullivan, Michael K. ORCID: https://orcid.org/0000-0002-3800-2330 and Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 (2023) Sex and gender differences in the management of chronic kidney disease and hypertension. Journal of Human Hypertension, (doi: 10.1038/s41371-023-00843-9) (Early Online Publication)

Mayne, Kaitlin J., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 and Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 (2023) Cardiovascular complications of chronic kidney disease. Medicine, 51(3), pp. 190-195. (doi: 10.1016/j.mpmed.2022.12.008)

Mayne, Kaitlin J., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178, Rutherford, Elaine, Thomson, Peter C., Traynor, Jamie P., Dey, Vishal ORCID: https://orcid.org/0000-0002-5108-4158, Lang, Ninian N. ORCID: https://orcid.org/0000-0001-8441-6887 and Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 (2023) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, 16(3), pp. 512-520. (doi: 10.1093/ckj/sfac248) (PMID:36865003) (PMCID:PMC9972818)

Mayne, Kaitlin J., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178 and Herrington, William G. (2023) Bioimpedance in CKD: an untapped resource? Nephrology Dialysis Transplantation, 38(3), pp. 583-585. (doi: 10.1093/ndt/gfac275) (PMID:36260361) (PMCID:PMC9976732)

The EMPA-KIDNEY Collaborative Group and (2023) Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), pp. 117-127. (doi: 10.1056/nejmoa2204233) (PMID:36331190) (PMCID:PMC7614055)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

Baigent, C. et al. (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, 400(10365), pp. 1788-1801. (doi: 10.1016/S0140-6736(22)02074-8) (PMID:36351458) (PMCID:PMC7613836)

Mayne, Kaitlin J., Shemilt, Richard, Keane, David F., Lees, Jennifer S. ORCID: https://orcid.org/0000-0001-6331-0178, Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 and Herrington, William G. (2022) Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review. Journal of Cardiac Failure, 28(11), pp. 1628-1641. (doi: 10.1016/j.cardfail.2022.08.005) (PMID:36038013)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Rankin, Alastair J. ORCID: https://orcid.org/0000-0001-9031-481X, Mayne, Kaitlin, Allwood-Spiers, Sarah, Hall Barrientos, Pauline, Roditi, Giles, Gillis, Keith A. ORCID: https://orcid.org/0000-0003-0003-4000 and Mark, Patrick B. ORCID: https://orcid.org/0000-0003-3387-2123 (2022) Will advances in functional renal magnetic resonance imaging translate to the nephrology clinic? Nephrology, 27(3), pp. 223-230. (doi: 10.1111/nep.13985) (PMID:34724286)

Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)